Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$17.1KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Allan White
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 2.67
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -12.92
Financials
Revenue
$17.1K-70.7%Net Income
$-2.87MEBITDA
$-2.86MFree Cash Flow
$-1.92MEPS (diluted)
$-1.28Shares Outstanding (diluted)
2.24M+67984.1%Operating Expenses
$2.25MCash & Debt
$5.94MReturn of Capital
$0.00Revenue by Segment (annual)
$0.60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $815.4K | $-14.03M | $-4.73 |
| 2024 | $2.52M | $-58.69M | $-520.93 |
| 2023 | $58.5K | $-37.41M | $-25.03 |
| 2022 | $0.00 | $-13.42M | $-0.31 |
| 2021 | $0.00 | $-3.42M | $-0.09 |
| 2020 | $0.00 | $-1.60M | $-0.04 |
| 2019 | $0.00 | $-821.9K | $-0.02 |
Valuation
ONCOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+333.33%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
View source ↗ - Newsbusinesswire.com·6h ago·Negative
Realbotix LLC Announces Bridge Loan from Onconetix LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has entered into a loan agreement with Onconetix, Inc. (“Onconetix”) for an unsecured bridge loan facility in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on
View source ↗ - Newsglobenewswire.com·11d ago·Negative
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
View source ↗
Earnings
Thu, Nov 12(in 8 weeks)
Consensus estimate $-45050.00 per share
Typical surprise +99.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.28 vs $-4505.00beat
- Thu, Aug 14$-2.02 vs $-204.00beat
- Thu, Jun 12$10.59 vs $-348.50beat
- Mon, Jun 2$-340.00 vs $-450.50beat
Estimates and results for ONCO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ONCO officers and directors.
- Bought
- $153k
- Sold
- $144k
3 trades
3 trades
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpbought
35 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ONCO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.